Our Products

"Valeo Pharma is focused on bringing products to Canadian physicians, providing them with more choice to meet the ever increasing needs of their patients."

- Marc Léger, Executive VP, Commercial Operations

Synacthen® Depot

Valeo Pharma currently markets PrSynacthen® Depot (1mg/mL). Synacthen is a synthetic ACTH product that is used in conditions where the production of natural cortisol and other hormones is desired. There are currently 17 indications for Synacthen approved by Health Canada. These include:

  • Acute exacerbations of Multiple Sclerosis
  • Rheumatoid arthritis
  • Lupus Erythematosus
  • Bell's Palsy
  • Ulcerative Colitis
  • Psoriatic Arthritis
  • Scleroderma
  • Nephrotic Syndrome
  • Adjuvant Treatment in cases of acute gout

For further information please consult the product monograph.

Synacthen® is a registered trademark of Novartis AG and is used under licence by Questcor Operations Ltd.

Joint Venture - Valeant Canada Inc

Valeo Pharma continues to market baclofen and vancomycin under a joint venture with Valeant Canada. These products represent our commitment to bring products needed by Canadian doctors when the market is underserved. For further information about these products, or if you need to report an adverse event, please contact Valeant Canada directly.

BACLOFEN Intrathecal

PrBaclofen Injection
0.05 mg/mL, 0.5 mg/mL and 2 mg/mL
For intrathecal injection and intrathecal infusion only

Baclofen is an antispastic agent that inhibits both monosynaptic and polysynaptic reflex transmission at the spinal level, possibly by decreasing excitatory neurotransmitter release from primary afferent terminals. Baclofen is an analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABAB), and may exert its effects by stimulation of the GABAB receptor subtype.

BACLOFEN Intrathecal (baclofen injection) is indicated for the management of patients with severe spasticity due to spinal cord injury or multiple sclerosis who are unresponsive to oral baclofen or who experience unacceptable side effects at effective oral doses.

BACLOFEN Intrathecal therapy may be considered as an alternative to destructive neurosurgical procedures.

For further information please consult the Canadian product monograph.

Vancomycin Hydrochloride for Injection

500mg/vial, 1g/vial, 10g/vial

Vancomycin is a tricyclic glycopeptide antibiotic derived from Amycolatopsis orientalis. It is primarily active against gram-positive organisms including staphylococci and streptococci. It is active against methicillin-resistant strains of Staphylococcus aureus and Staphylococcus epidermidis.

Vancomycin Hydrochloride for Injection, administered intravenously, is indicated for the treatment of severe or life-threatening staphylococcal infections in patients who cannot receive or have failed to respond to penicillins or cephalosporins or who have infections with staphylococci resistant to other antibiotics, including methicillin.

For further information please consult the Canadian product monograph.